Exelixis
EXEL
#2109
Rank
NZ$12.18 B
Marketcap
$42.70
Share price
-1.53%
Change (1 day)
17.39%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/S ratio for Exelixis (EXEL)

P/S ratio as of September 2024 (TTM): 3.73

According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.73141. At the end of 2024 the company had a P/S ratio of 3.25.

P/S ratio history for Exelixis from 2001 to 2024

PS ratio at the end of each year

Year P/S ratio Change
20243.25-20.27%
20234.0826.93%
20223.21-20.32%
20214.03-36.08%
20206.3113.98%
20195.53-19.92%
20186.91-65.24%
201719.9-11.96%
201622.6-34.72%
201534.6207.89%
201411.2-68.88%
201336.1104.02%
201217.7698.31%
20112.22-54.29%
20104.85-7.48%
20095.2416.52%
20084.50-43.54%
20077.97-9.01%
20068.76-15.35%
200510.3-23.26%
200413.538.21%
20039.75-9.02%
200210.7-52.9%
200122.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
2.15-42.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
2.83-24.26%๐Ÿ‡ซ๐Ÿ‡ท France
4.75 27.42%๐Ÿ‡บ๐Ÿ‡ธ USA
2.15-42.43%๐Ÿ‡บ๐Ÿ‡ธ USA
5.88 57.61%๐Ÿ‡บ๐Ÿ‡ธ USA
4.58 22.72%๐Ÿ‡บ๐Ÿ‡ธ USA
3.00-19.66%๐Ÿ‡บ๐Ÿ‡ธ USA
3.48-6.80%๐Ÿ‡บ๐Ÿ‡ธ USA
5.53 48.16%๐Ÿ‡บ๐Ÿ‡ธ USA